SAB Biotherapeutics Files 8-K on Definitive Agreement & Asset Deal
Ticker: SABSW · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1833214
| Field | Detail |
|---|---|
| Company | Sab Biotherapeutics, Inc. (SABSW) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $601,630, $50,135.90 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, acquisition, disposition
TL;DR
SAB Biotherapeutics (fka Big Cypress) filed an 8-K on Jan 30th for a material agreement & asset deal.
AI Summary
SAB Biotherapeutics, Inc. (formerly Big Cypress Acquisition Corp.) filed an 8-K on February 5, 2025, reporting on events as of January 30, 2025. The filing indicates the entry into a material definitive agreement and the completion of an acquisition or disposition of assets. SAB Biotherapeutics, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing signals significant corporate activity for SAB Biotherapeutics, Inc., potentially involving mergers, acquisitions, or asset sales that could impact its business operations and shareholder value.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and completion of an acquisition/disposition, which are significant corporate events that can carry inherent risks.
Key Players & Entities
- SAB Biotherapeutics, Inc. (company) — Registrant
- Big Cypress Acquisition Corp. (company) — Former Company Name
- January 30, 2025 (date) — Earliest Event Reported
- February 5, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
FAQ
What is the nature of the material definitive agreement entered into by SAB Biotherapeutics, Inc. as of January 30, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this summary.
What type of acquisition or disposition of assets was completed by SAB Biotherapeutics, Inc.?
The filing states the completion of an acquisition or disposition of assets, but the specifics of the transaction are not detailed in this summary.
When was SAB Biotherapeutics, Inc. formerly known as Big Cypress Acquisition Corp.?
The date of the name change from Big Cypress Acquisition Corp. to SAB Biotherapeutics, Inc. was November 20, 2020.
What is the primary business of SAB Biotherapeutics, Inc. according to its SIC code?
SAB Biotherapeutics, Inc. is classified under SIC code 2836, which pertains to Biological Products (no diagnostic substances).
Where is SAB Biotherapeutics, Inc. headquartered?
SAB Biotherapeutics, Inc.'s business and mailing address is 777 W 41ST ST, SUITE 401, MIAMI BEACH, FL 33140.
Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-02-05 17:00:10
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq
- $601,630 — le under the Sanford Lease Agreement is $601,630.82, with monthly rent being $50,135.90.
- $50,135.90 — is $601,630.82, with monthly rent being $50,135.90. The Sanford Lease Agreement has an ini
Filing Documents
- sabs-20250130.htm (8-K) — 46KB
- sabs-ex10_1.htm (EX-10.1) — 155KB
- 0000950170-25-014627.txt ( ) — 370KB
- sabs-20250130.xsd (EX-101.SCH) — 46KB
- sabs-20250130_htm.xml (XML) — 6KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On January 30, 2025, SAB Biotherapeutics, Inc. (the "Company") entered into a lease agreement, dated and effective February 1, 2025 (the "Sanford Lease Agreement"), with Sanford Health, a South Dakota non-profit corporation ( the "Landlord"). The Sanford Lease Agreement provides for a lease area of 21,014 from the Landlord to the Company, located at 2301 East 60th Street North, Sioux Falls, South Dakota 57104. Annual rent payable under the Sanford Lease Agreement is $601,630.82, with monthly rent being $50,135.90. The Sanford Lease Agreement has an initial five-year term ending on December 31, 2029. The foregoing description of the Sanford Lease Agreement does not purport to be complete, and is qualified in its entirety by the full text of the Sanford Lease Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K, and is incorporated herein by reference. Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 10.1 * Lease Agreement between SAB Biotherapeutics, Inc. and Sanford Health, dated February 1, 2025 . 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document. * Confidential treatment has been granted or requested with respect to portions of this exhibit.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: February 5, 2025 By: /s/ Samuel J. Reich Samuel J. Reich Chief Executive Officer